ADVANCED STAGES OF PARKINSON'S DISEASE

Keiran K Tuck MBBS



Honorary Board Member at Parkinson Wellness Project

Outline

► The PD Hydra

- Cognitive changes and dementia
- Mortality
- Long Term Care and PD

ESSAY

ON THE

SHAKING PALSY.

BY

JAMES PARKINSON, WEMBER OF THE ROYAL COLLEGE OF SUBGROOMS.

LONDON: PRIMER BY WRITTINGTAM AND ROWLAND, Greenel Scient,

FOR SHERWOOD, NEELY, AND JONES, PATERNOTES BOW.


1817.

. L.



Cardinal Features of PD

- $\blacktriangleright \text{ Shaking } \rightarrow \text{Tremor}$
- ► Palsy → Bradykinesia
- ▶ Difficulty with gait and falls \rightarrow Postural Instability
- ▶ ??? \rightarrow Rigidity



Non Motor Features of PD



Drooling

Olfactory and taste dysfunction Choking and swallowing difficulties Nausea and vomiting Constipation Fecal incontinence Bladder dysfunction Pain Weight loss & weight gain Cognitive dysfunction and Dementia Hallucinations Depression Anxiety Apathy Sexual dysfunction Orthostatic hypotension Excessive daytime sleepiness Insomnia REM sleep behaviour disorder Restless leg syndrome Leg swelling Excessive sweating Diplopia and visual abnormalities Delusions Impulse control disorders

But wait... there's more!

Caregiver strain

- Spiritual distress
- ► Transportation

. . .

- Relationships with Friends and Family
- Planning for the future


MOTIVATIONALBUCK.COM



SURE, I CAN HANDLE THE LOAD. NO PROBLEM.


"The early stages, including problems of motor complications from medications are largely treatable. It is the later stages... that are virtually untreatable at present."

Fahn, Jankovic and Hallet. Principles and Practice of Movement Disorders 2nd Ed.




PD management requires a team approach involving patients, families, caregivers and numerous clinicians





Cognitive Impairment



Terms

Pseudo-dementia


subjective cognitive impairment caused by a medical or psychological problem


Mild Cognitive Impairment

- subjective cognitive impairment
- Iower than normal score on formal cognitive test
- no obvious cause
- Dementia impaired daily function
 - Alzheimer's
 - Lewy Body Dementia
 - Vascular
 - Mixed
 - others

Diagnosis of the specific type of dementia is difficult without brain tissue sample

Often it doesn't really matter





Incidence

Within three years of diagnosis

- ▶ 25% converted to MCI
 - 20% converted to dementia while 28% reverted back to a state of normal cognitive function
 - > To me this indicates a large amount of pseudo-dementia

2% converted to dementia

Prevalence

Movement Disorders Vol. 23, No. 6, 2008, pp. 837–844 © 2008 Movement Disorder Society

The Sydney Multicenter Study of Parkinson's Disease: The Inevitability of Dementia at 20 years

Mariese A. Hely, MBBS,^{1*} Wayne G.J. Reid, PhD,¹ Michael A. Adena, PhD, ASTAT,² Glenda M. Halliday, PhD,³ and John G.L. Morris, MD¹

Dementia is present in 83%

17 people with dementia had postmortems. 8 had diffuse Lewy bodies as the only cause of dementia, while others had mixed neuropathology.

Risk Factors

Atypical parkinsonism

- PSP, MSA, DLB, Vascular parkinsonism
- Hallucinations
- Greater motor impairment
- Longer duration of illness
- Male gender
- Older age

Prevention

► Exercise

- Social and mental activity
- Managing other medical issues






Management - Medications

Cholinesterase inhibitors (donepezil, rivastigmine)

NMDA receptor antagonist (memantine)

Quetiapine, clozapine, pimavanserin (USA)



Management - Lifestyle

Happy and Safe

- Home safety
- Driving safety
- Enjoy life
- Caregiver support
- Advanced care planning documents



Mortality in PD



Preferences of Patients With Parkinson's Disease for Communication About Advanced Care Planning

Keiran K. Tuck, MBBS¹, Lissa Brod, MD¹, John Nutt, MD¹, and Erik K. Fromme, MD² American Journal of Hospice & Palliative Medicine[®] 00(0) 1-10 © The Author(s) 2013 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/1049909113504241 ajhpm.sagepub.com

SAGE

Table 2. Percentage Responding "When Should your doctor discuss"

	At the Time of Diagnosis	During the Next Few Visits	Only When the Disease Worsens	Wait Until I Ask	Never	Unsure
Treatment goals and options	73.2	19.9	4.1	1.6	0	1.2
Symptoms and treatment side effects	73.9	19.7	3.6	2.4	0	0.4
Involving family in disease discussion	56.6	17.3	7.2	15.3	1.2	2.4
Advance care planning documents	25.2	24.8	19.5	12.6	5.7	12.2
Life expectancy	23.8	14.1	25.0	23.8	2.0	11.3
Planning for end-of-life care	13.0	14.2	39.3	20.2	1.6	11.7
Family communication about end-of-life care	12.5	13.3	43.I	17.3	3.2	10.5
End-of-life care options	12.1	9.3	48.4	16.9	0.8	12.5

Table 3. Who Should Ideally Raise These Issues?

% of Respondents Who Say This Person Should Ideally Raise Questions Of ...

	Life Expectancy	Advanced Care Planning Documents	End-of-Life Care Options
Patient	65.9	74.5	77.6
PCP	27.8	38.9	41.6
Neurologist	50	38.5	42
Should not be discussed	6.7	1.2	1.2
Unsure n = 252/267 (94.4%)	16.3	10.9	9.6

Abbreviation: PCP, primary care physician.

Parkinsonism and Related Disorders xxx (2015) 1–5 Contents lists available at ScienceDirect




Parkinsonism and Related Disorders



Life-sustaining treatment orders, location of death and co-morbid conditions in decedents with Parkinson's disease

Keiran K. Tuck ^a, Dana M. Zive ^b, Terri A. Schmidt ^{b, c}, Julie Carter ^a, John Nutt ^a, Erik K. Fromme ^{c, *}



Place of Death and POLST Use


Fig. 1. Place of death and POLST use.

Mortality in Parkinson's Disease: A Systematic Review and Meta-analysis

Angus D. Macleod, MRCP,1* Kate S.M. Taylor, MD,2 and Carl E. Counsell, MD1

¹Institute of Applied Health Sciences, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, UK ²Raigmore Hospital, Inverness, UK

Movement Disorders, Vol. 29, No. 13, 2014






FIG. 4. Meta-analysis of time from disease onset or diagnosis to death in a retrospective series of deceased patients using a DerSimonian and Laird random effects model. The I² heterogeneity statistic is 97.4%: a pooled estimate is therefore not presented. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

median age at death was 83 years (range 47-101 years)



Tuck et al 2015

Although patients presenting with idiopathic parkinsonism have reduced survival, the survival is highly dependent on the type and characteristics of the parkinsonian disorder. Patients with Parkinson disease presenting with normal cognitive function seem to have a largely normal life expectancy

Backstroem 2018

Predictors of Survival in Patients With Parkinson Disease

Allison W. Willis, MD; Mario Schootman, PhD; Nathan Kung, MD; Bradley A. Evanoff, MD, MPH; Joel S. Perlmutter, MD; Brad A. Racette, MD

- Retrospective cohort study of 138 000 Medicare beneficiaries with incident PD who were identified in 2002 and followed up through 2008
- ▶ Thirty-five percent of PD cases lived more than six years.
- Sex and race significantly predicted survival:
 - female (HR 0.74, 0.73– 0.75)
 - Hispanic (HR 0.72, 0.65–0.80)
 - Asian (HR 0.86, 0.82–0.91)
- Dementia/cognitive impairment, diagnosed in 69.6% of cases, most often in Blacks (78.2%) and women (71.5%), was associated with a greater likelihood of death (HR 1.72, 1.69–1.75).



The Sydney Multicenter Study of Parkinson's Disease: The Inevitability of Dementia at 20 years

Mariese A. Hely, MBBS,^{1*} Wayne G.J. Reid, PhD,¹ Michael A. Adena, PhD, ASTAT,² Glenda M. Halliday, PhD,³ and John G.L. Morris, MD¹

only 14/30 (47%) still see their neurologist after 20 years

Nursing Homes

doi:10.1111/j.1468-1331.2008.02380.x

Parkinson's disease and nursing home placement: the economic impact of the need for care

C. Vossius^{a,b}, O. B. Nilsen^{b,d} and J. P. Larsen^{a,b,c}

^aDepartment of Neurology and ^bThe Norwegian Centre for Movement Disorders, Stavanger University Hospital, Stavanger; ^cInstitute of Medicine, University of Bergen, Bergen; and ^dDepartment of Mathematics and Natural Science, University of Stavanger, Stavanger, Norway

	Patients with PD	Controls
Number at baseline	108	864
Males/females (%)	49/51	49/51
Age at baseline in years (SD)	73.8 (7.6)	73.8 (7.6)
Admitted to nursing home at baseline (%)	15 (14)	24* (2.8)
Home-dwelling at baseline (%)	93 (86)	840* (97.2)
Number during follow up	93	840
Admitted to nursing home during study period (%)	49 (52.7)	211* (26)
Age at admission in years (SD)	78.9 (5.5)	84.4* (5.4)
Time from baseline to admission in years (SD)	4.9 (2.9)	6.14* (3.6)
Time from admission to death in years (SD)	2.9 (2.6)	1.2* (1.5)
Surviving and home-dwelling (%)	16 (17.2)	353* (42)
Died during study period (%)	70 (75.3)	442* (53)
Died in nursing home (%)	42 (85.7)	172 (82)
Died at home (%)	28 (30.1)	270 (32.4)
Age at death in years (SD)	80.5 (5.3)	82.7* (6.4)

Table 2 Patients with Parkinson's disease (PD) compared with controls at baseline and during 12-year follow-up

*P < 0.05.





Figure 1 Kaplan-Meier curves for time to nursing home placement for patients with Parkinson's disease (PD) and control individuals.



What happens in Nursing Homes



Perspectives on Parkinson Disease Care in Dutch Nursing Homes

Anouke van Rumund MD^{a,*}, Nico Weerkamp MD^b, Gerrit Tissingh MD, PhD^b, Sytse U. Zuidema MD, PhD^c, Raymond T. Koopmans MD, PhD^d, Marten Munneke PhD^{a,e}, Petra J.E. Poels MD, PhD^a, Bastiaan R. Bloem MD, PhD^a

Survey of 15 nursing home residents and their caregivers in the Netherlands

(CrossMark

Table 3

Examples of Related Codes and Quotes Categorized by Core Theme

Core Theme	Code	Quote
Emotional support and empathy	Lack of support/empathy for patient	"An actual talk about emotional aspects is not possible there. And I certainly need that, really, a little support and empathy." (Patient, male 78 years)
Organization of care	PD nurse as mediator between nursing home and neurologist	"So I think there would be a faster feedback to the neurologist through a PD nurse." (PD nurse)
	Involvement of neurologist	"In a late stage the neurologist is not involved anymore." (PD nurse)
	Staff occupancy	"They need to work harder because
		they get less staff members and, well, they do their best but there is not enough money and not enough time.
		And they are unable to hire new ones because there is no money for it anymore." (Patient, female 79 years)
Staff knowledge	Medication given too late	"Yes, here I'm always struggling to get my medication in time." (Patient, female 79 years)
	Medication combined with proteins	"They are not aware that it works like that, that medication and food can't be taken at once." (Patient, female 70 years)
	Lack of PD knowledge among nurses	"And what really bothers me is that PD knowledge is just poor." (Spouse, female)

PD, Parkinson disease.



Conclusions: PD care in Dutch nursing homes is suboptimal according to residents, informal caregivers, and health care workers. Three core areas for improvement were identified, including greater attention for psychosocial problems, improved PD-specific knowledge among nursing home staff, and better collaboration with hospital staff trained in movement disorders.



Contents lists available at Science Direct

Parkinsonism and Related Disorders

journal homepage: www.elsevier.com/locate/parkreldis

Diagnostic accuracy of Parkinson's disease and atypical parkinsonism (D_{GrossMark} in nursing homes

N.J. Weerkamp ^{a, b}, G. Tissingh ^a, P.J.E. Poels ^b, S.U. Zuidema ^c, M. Munneke ^b, R.T.C.M. Koopmans ^d, B.R. Bloem ^{b, e, *}

Table 1 Diagnostic changes in 53 of 2

Parkinsonisn

Diagnostic changes in 53 of 258 nursing home patients. Parkinsonism and PD rejected (n = 22)New- and rejected diagnosis within parkinsonian spectrum (n = 31)PD newly diagnosed (19) Parkinsonism rejected (17) Parkinsonism → PD (9) → AD (5) → hypertonia after stroke (4) $- VP \rightarrow PD(3)$ → contractures (2) MSA→ PD (2) 'falls' → PD (1) → lumbar stenosis(1) → polyneuropathy (1) $- AD \rightarrow PD(1)$ → hypertonia in MS (1) - DLB \rightarrow PD (1) VD → PD (1) → multimorbidity (1) 'frontal dementia' → PD (1) → head titubation (1) \rightarrow ET (1) DLB newly diagnosed (5) PD rejected (5) $- AD \rightarrow DLB(2)$ \rightarrow AD (1) MSA → DLB (2) → myoclonus eci (1) 'dementia' → DLB(1) → orthopedic (1) → stroke (1) → akathisia (1) MSA newly diagnosed (2) 'falls' → MSA (1) parkinsonism → MSA (1) PSP newly diagnosed (1) - DLB \rightarrow PSP(1) PD/MSA rejected (4) PD → parkinsonism(3) MSA → parkinsonism (1) The diagnosis in italics represents the groups of diagnosis newly made or rejected,

The diagnosis in italics represents the groups of diagnosis newly made or rejected. All diagnosis behind the arrows (\rightarrow) represents the individual new diagnosis made in the study.

VD – vascular dementia ET – essential tremor MS – multiple sclerosis VP – vascular parkinsonism.

MSA – multiple system atrophy AD – Alzheimer's disease PSP – progressive supranuclear palsy.

Motor Profile and Drug Treatment of Nursing Home Residents with Parkinson's Disease

Nico J. Weerkamp, MD, *[†] Sytse U. Zuidema, MD, PhD, ^{‡//} Gerrit Tissingh, MD, PhD, * Petra J. E. Poels, MD, PhD, [†] Marten Munneke, PhD, [†] Raymond T. C. M. Koopmans, MD, PhD, [‡] and Bastiaan R. Bloem, MD, PhD^{†§}

JAGS 60:2277-2282, 2012






Figure 2. Presence and severity of "off" periods.

Poor QOL for PD in NH

- PDQ-8 higher than outpatient cohorts
- PDQ mainly driven by NMS



Nonmotor Symptoms in Nursing Home Residents with Parkinson's Disease: Prevalence and Effect on Quality of Life

Nico J. Weerkamp, MD, *[†] Gerrit Tissingh, MD, PhD, * Petra J.E. Poels, MD, PhD, [†] Systse U. Zuidema, MD, PhD, [‡] Marten Munneke, PhD, [†] Raymond T.C.M. Koopmans, MD, PhD, [§] and Bastiaan R. Bloem, MD, PhD^{\parallel}

JAGS 61:1714-1721, 2013

Characteristic	Value
Age, mean \pm SD	78.7 (6.4)
Female, n (%)	40 (55)
Disease duration, years, mean \pm SD	10.1 (7.3)
Length of stay, months, mean \pm SD	22.5 (27.1)
Hoehn and Yahr stage, n (%)	
2	1 (1)
3	8 (11)
4	28 (38)
5	36 (49)
Taking levodopa, n (%)	67 (92)
Taking dopamine agonist, n (%)	15 (21)
Levodopa equivalent dose, mg, mean (range)	673 (0-1,600
Taking antidepressants, n (%)	18 (25)
Taking atypical antipsychotics, n (%)	25 (34)
Taking cholinesterase inhibitors, n (%)	21 (29)
Taking anticholinergics, n (%)	9 (12)
Taking benzodiazepines, n (%)	31 (42)

SD = standard deviation.

Table 3.	Prevalence	of	Individual	Non-Motor	Symp-
toms Scale	Items				

Item Number and Symptom	n (%)
4. Fatigue	56 (78.9)
22. Urgency ^a	51 (75.0)
17. Forget things or events	49 (69.0)
10. Seem sad	47 (66.2)
8. Lack motivation	45 (63.4)
19. Saliva	45 (63.4)
3. Daytime sleep	43 (60.6)
Lost interest surroundings	43 (60.6)
23. Frequency ^a	40 (58.8)
24. Nocturia ^a	39 (57.4)
16. Concentration	40 (56.3)
6. Restless legs	38 (53.5)
9. Feel nervous	38 (53.5)
5. Difficulty falling asleep	37 (52.1)
18. Forget to do things	36 (50.7)
1. Light headedness	34 (47.9)
21. Constipation	34 (47.9)
20. Swallowing	30 (42.3)
Difficulty experiencing pleasure	27 (38.0)
11. Flat mood	25 (35.2)
15. Double vision	25 (35.2)
13. Hallucinations	17 (23.9)
27. Pains	17 (23.9)
30. Excessive sweating	15 (21.1)
14. Delusions	14 (19.7)
29. Weight change	13 (18.3)
28. Taste or smell	8 (11.3)
25. Interest in sex	4 (5.7)
26. Problems having sex	4 (5.7)
2. Fainting	4 (5.6)

*The urinary domain was incompletely collected in three residents because of an indwelling catheter.

Death in Nursing Homes

Predictors of mortality among nursing home residents with a diagnosis of Parkinson's disease

Hubert H. Fernandez^{1,2} Model, Kate L. Lapane³ Model

- \blacktriangleright 3-year mortality rate = 50%.
- Independent predictors of death:
 - Advanced age (relative rate (RR) 2.22; 95% confidence interval (CI) 1.99–2.47, for patients 85+ years),
 - male gender (RR 1.73; 95% CI1.60–1.87),
 - severe functional impairment (RR 1.81; 95% CI 1.53–2.13)
 - cognitive impairment (RR 1.54; 95% CI1.38–1.72),
 - vision problems (RR 1.25; 95% CI 1.20–1.57),
 - pressure ulcers (RR 1.25; 95% 1.14–1.37),
 - congestive heart failure (RR 1.49; 95% CI 1.35–1.65),
 - diabetes mellitus (RR 1.22; 95% 1.11–1.35)
 - pneumonia (RR 1.39; 95% CI 1.09–1.77
 - African-Americans and other minority groups were less likely to die relative to white PD residents.

Nursing home and end-of-life care in Parkinson disease

Retrospective cohort study

- 469,055 elderly Medicare beneficiaries with a diagnosis of PD (ICD-9 codes 332 (Parkinson disease) or 332.0 (paralysis agitans)
 - Those with a secondary code such as secondary parkinsonism (332.1) or other degenerative diseases of the basal ganglia (333.0) were excluded from analysis.
 - > 24% (n = 113,668) had claims consistent with residence in a LTCF

Table 2 Demographic and clinical characteristics of LTCF and community-dwelling individuals with Parkinson disease*					
Characteristic		Community (n = 355,387)	LTCF (n = 113,668)		
Race					
White		326,862 (92.0)	104,866 (92.3)		
Black		17,013 (4.8)	6,433 (5.7)		
Asian		3,918 (1.1)	839 (0.7)		
Hispanic		7,594 (2.1)	1,530 (1.3)		
Sax					
Male		181,190 (51.0)	47,472 (41.8)		
Female		174,197 (49.0)	66,196 (58.2)		
Age, y					
65-69		37,418 (10.5)	4,570 (4.0)		
70-74		64,666 (18.2)	11,295 (9.9)		
75-79		90,600 (25.5)	22,360 (19.7)		
80-84		87,138 (24.5)	31,578 (27.8)		
85+		75,565 (21.3)	43,865 (38.6)		
Comorbid media	al diagnosis ^b				
Atrial fibrillat	lon	47,551 (13.4)	16,923 (14.9)		
Dementia		104,199 (29.3)	74,930 (65.9)		
Myocardial in	farction	12,140 (3.4)	3,872 (3.4)		
Congestive h	eart failure	107,951 (30.4)	47,248 (41.6)		
Colorectal ca	ncer	7,343 (2.1)	2,375 (2.1)		
COPD		59,225 (16.7)	24,228 (21.3)		
Diabetes mel	litus	85,819 (24.1)	28,352 (24.9)		
Hip fracture		18,168 (5.1)	14,086 (12.4)		
Ischemic hear	t disease	124,064 (34.9)	53,859 (47.4)		
Stroke/TIA		74,709 (21.0)	34,466 (30.3)		

Abbreviations: COPD = chronic obstructive pulmonary disease; LTCF = long-term care facility. Data are n (%).

* Among all fee-for-service Medicare beneficiaries older than 65 years (year = 2002).

^b According to the Centers for Medicare & Medicaid Services Chronic Condition Warehouse.

Sex and age ratios consistent with other LTCF data

Hospice Utilization

- Almost 85% (n = 80,877) of nursing home residents with PD died between January 1, 2003, and December 31, 2005.
- Hospice care was utilized by 54.2% (n = 43,805) of the decedents
- A logistic regression model determined that neurologist-treated patients were more than twice as likely to receive hospice care before death (AOR 2.35, 95% CI 2.24–2.47).

Neurologist-treated patients were also healthier:

- Lower odds of dementia (AOR 0.41, 95% CI 0.40–0.42),
- ▶ Lower odds of hip fracture (AOR 0.74, 95% CI 0.70–0.77),
- Lower odds of congestive heart failure (AOR 0.67, 95% CI 0.65–0.70)
- Lower odds of diabetes (AOR 0.68, 95% CI 0.65–0.70)
- Lower odds of ischemic heart disease (AOR 0.78, 95% CI 0.76–0.80)
- ▶ Lower odds of stroke/TIA (AOR 0.69, 95% CI 0.67–0.72).

Summary

- PD is a complex life threatening illness
- A large proportion of people with PD end up in Nursing Homes
- Nursing home care may be inadequate
- As part of an interdisciplinary team, neurologists can make a difference in end-of-life care



Questions?

